Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on February 15, 2023, the Compensation Committee of Sutro’s Board of Directors granted 90,000 shares of Sutro Biopharma stock options and 130,000 restricted stock units (RSUs) of Sutro common stock. These grants were made as an inducement material to the employees’ acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (STRO)
- Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
- Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- MoBot’s Stock Market Highlights – 04/30/25 06:00 PM
- MoBot’s Stock Market Highlights – 04/30/25 05:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/30/25 04:00 PM